A Study of 1592U89 in HIV-Infected Adults
Not Applicable
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00002200
- Lead Sponsor
- Glaxo Wellcome
- Brief Summary
The purpose of this study is to see if it is safe and effective to give 1592U89 to HIV-positive adults. This study also examines the influence previous anti-HIV treatment has on the effectiveness of 1592U89.
- Detailed Description
Patients receive open-label 1592U89 administered orally in combination with at least one other antiretroviral agent that the patient has not previously received.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Glaxo Wellcome Inc
🇺🇸Research Triangle Park, North Carolina, United States